

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number  
**WO 2005/014566 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 307/82**,  
A61K 31/343, A61P 35/00

(21) International Application Number:  
PCT/US2004/025480

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/494,165 7 August 2003 (07.08.2003) US

(71) Applicant (for all designated States except US): **BAYER  
PHARMACEUTICALS CORPORATION** [US/US];  
400 Morgan Lane, West Haven, Connecticut 06516 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZHANG, Chengzhi**  
[CA/US]; 193 Mulberry Lane, Orange, Connecticut  
06477 (US). **DUMAS, Jacques** [US/US]; 98 Farmview  
Road, Bethany, Connecticut 06477 (US). **LADOUCEUR,**  
**Gaetan, H.** [CA/US]; 103 Golden Hill Drive, Guilford,  
Connecticut 06437 (US). **ZHAO, Qian** [CN/US]; 93 Hintz  
Drive, Wallingford, Connecticut 06492 (US). **HENTE-**  
**MANN, Martin, F.** [US/US]; 80 Morris Street, Hamden,  
Connecticut 06517 (US). **VERMA, Sharad, K.** [US/US];  
29 Harbour Close, New Haven, Connecticut 06519 (US).  
**ZHU, Qingming** [CN/US]; 11 Bassett Street, Apt. D4,  
West Haven, ct 06516 (US). **LAVOIE, Rico, C.** [CA/US];  
84 Hubbard Place, Hamden, Connecticut 06517 (US).  
**FAN, Jianmei** [CN/US]; 121 October Hill Road, Hamden,  
Connecticut 06518 (US). **PHILLIPS, Barton** [US/US];  
498 Whitney Avenue, Apt. 3D, New Haven, Connecticut  
06511 (US).

(74) Agents: **GREENMAN, Jeffrey, M.** et al.; Bayer Phar-  
maceuticals Corporation, 400 Morgan Lane, West Haven,  
Connecticut 06516 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

[Continued on next page]

(54) Title: **BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS**



(I),

(57) Abstract: The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*